To understand the size and impact of costs to clinical trial participants, the Office of the Assistant Secretary for Planning and Evaluation (ASPE) conducted an exploratory survey of 112 U.S. adults who participated in an oncology clinical trial between 2018-2024.
Cancer
Reports
Displaying 1 - 8 of 8. 10 per page. Page 1.
Advanced SearchASPE Issue Brief
Medicare Part D Enrollees Reaching the Out-of-Pocket Limit by June 2024
The Inflation Reduction Act established a limit on out-of-pocket spending (“the 2024 cap”) for enrollees with very high prescription drug spending in Medicare Part D, for the first time in the history of the program.
ASPE Issue Brief
Participant Diversity by Race, Ethnicity, and Sex in Rare Disease Clinical Trials: A Case Study of Eight Rare Cancers
Rare cancer clinical trials appear to enroll less diverse participants than clinical trials more broadly and therefore may require additional considerations or unique solutions to diversify participant recruitment. These differences persisted within both NIH and non-NIH funded trials.
Report
Linking State Health Care Data to Inform Policymaking: Opportunities and Challenges
This posting includes a report prepared by the RAND Corporation, “State All Payer Claims Databases Understanding the Current Landscape and Challenges to Use,” which builds on a 2021 report “The History, Promise and Challenges of State All Payer Claims Databases.” The new report provides additional detail on the objectives of and use cases for APCDs, the current APCD landscape, and implementatio
Case Study
The Importance of Radiology and Pathology Communication in the Diagnosis and Staging of Cancer: Mammography as a Case Study
The ASPE Technical Expert Panel on Improving Cancer Policy Research through Information Technology Submitted by